Literature DB >> 6219834

Complement-dependent lymphocytotoxic antibodies (CLA) in systemic lupus erythematosus preferentially inhibit the generation of alloreactive cytotoxic T cells in secondary CML.

C Huber, R Pfister, G Stingl.   

Abstract

Complement-dependent lymphocytotoxic autoantibodies (CLA) are invariably present in sera of patients with active systemic lupus erythematosus (SLE). This study aimed to test for the influence of such antibodies on the in vitro generation of human alloantigen reactive proliferative and cytotoxic T cell responses. Unsensitized or alloantigen primed memory cells were pre-treated with CLA in the presence or absence of complement. Following stimulation of the remaining cells with allogeneic peripheral blood mononuclears, the proliferative and cytotoxic capacity was evaluated. Results indicated that only pre-treatment with CLA and complement influenced these reactions whereas in the absence of complement antibodies were totally ineffective. Pre-treatment of unsensitized precursor cells reduced and delayed both proliferative and cytotoxic reactivity; in contrast, pre-treatment of memory cells exclusively reduced cellular cytotoxicity. It thus appears that such SLE associated autoantibodies in the presence of complement are capable of modifying the balance between different subsets of alloreactive T cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6219834      PMCID: PMC1536823     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Suppressor T-cell abnormality in idiopathic systemic lupus erythematosus.

Authors:  N I Abdou; A Sagawa; E Pascual; J Hebert; S Sadeghee
Journal:  Clin Immunol Immunopathol       Date:  1976-09

2.  Family distribution of lymphocytotoxins in Hodgkin's disease.

Authors:  J R Mendius; R J DeHoratius; R P Messner; R C Williams
Journal:  Ann Intern Med       Date:  1976-02       Impact factor: 25.391

3.  Selective loss of suppressor cell function in New Zealand mice induced by NTA.

Authors:  L W Klassen; R S Krakauer; A D Steinberg
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

4.  THYMIC CHANGES IN THE MOUSE STRAIN NZB IN RELATION TO THE AUTO-IMMUNE STATE.

Authors:  F M BURNET; M C HOLMES
Journal:  J Pathol Bacteriol       Date:  1964-07

5.  Linear density gradient separation of human lymphocyte subsets. I. Analysis by mixed leukocyte culture and cell-mediated lympholysis responses.

Authors:  K S Zier; C Huber; H Braunsteiner
Journal:  Eur J Immunol       Date:  1977-06       Impact factor: 5.532

6.  Lymphocytotoxic antibodies in family members of patients with systemic lupus erythematosus.

Authors:  R J DeHoratius; R P Messner
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

7.  Anti-beta2-microglobulin lymphocytotoxic autoantibodies in systemic lupus erythematosus.

Authors:  J P Revillard; C Vincent; S Rivera
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

8.  Expression and specificity of FcIgG receptor sites on neoplastic lymphocytes.

Authors:  C Huber; H D Flad; K Nilsson; H Wigzell; G Michlmayr; H Frischauf; H Braunsteiner
Journal:  Blood       Date:  1978-11       Impact factor: 22.113

9.  The role of adherent HLA-DR+ mononuclear cells in autologous and allogeneic MLR.

Authors:  C Huber; U Fink; W Leibold; F Schmalzl; P A Peterson; L Klareskog; H Braunsteiner
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

10.  Studies of immune functions of patients with systemic lupus erythematosus. I. Dysfunction of suppressor T-cell activity related to impaired generation of, rather than response to, suppressor cells.

Authors:  T Sakane; A D Steinberg; I Green
Journal:  Arthritis Rheum       Date:  1978 Jul-Aug
View more
  1 in total

1.  Serum lymphocytotoxic activity in leprosy.

Authors:  F N Rasheed; M Locniskar; D J McCloskey; R S Hasan; T J Chiang; P Rose; R de Soldenhoff; H Festenstein; K P McAdam
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.